Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Vericel Corproation (VCEL)

Vericel Corproation (VCEL)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 641,930
  • Shares Outstanding, K 45,111
  • Annual Sales, $ 117,850 K
  • Annual Income, $ -9,670 K
  • 60-Month Beta 3.00
  • Price/Sales 5.48
  • Price/Cash Flow 71.31
  • Price/Book 5.82

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/20
See More
  • Average Estimate -0.27
  • Number of Estimates 3
  • High Estimate -0.23
  • Low Estimate -0.32
  • Prior Year -0.05
  • Growth Rate Est. (year over year) -440.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
13.31 +8.04%
on 05/04/20
15.95 -9.84%
on 05/11/20
-0.18 (-1.24%)
since 04/29/20
3-Month
6.78 +112.09%
on 03/19/20
15.95 -9.84%
on 05/11/20
-1.06 (-6.87%)
since 02/28/20
52-Week
6.78 +112.09%
on 03/19/20
19.95 -27.92%
on 07/15/19
-1.54 (-9.67%)
since 05/29/19

Most Recent Stories

More News
Zacks.com featured highlights include: Myriad Genetics, Cinemark, Vericel and IDEXX Laboratories

Zacks.com featured highlights include: Myriad Genetics, Cinemark, Vericel and IDEXX Laboratories

MYGN : 14.53 (+0.83%)
IDXX : 308.88 (+0.90%)
CNK : 15.03 (-1.76%)
VCEL : 14.38 (+1.05%)
Dump These 4 Toxic Stocks or Sell Short for Timely Profits

Identifying toxic stocks and discarding them at the right time is the key to guard your portfolio from big losses.

MYGN : 14.53 (+0.83%)
IDXX : 308.88 (+0.90%)
CNK : 15.03 (-1.76%)
VCEL : 14.38 (+1.05%)
Vericel to Present at the UBS Virtual Global Healthcare Conference on Wednesday, May 20, 2020

Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, president and CEO, will present the latest company...

VCEL : 14.38 (+1.05%)
Vericel Reports First Quarter 2020 Financial Results

Product Revenues of $26.7 Million Increase 22% Over First Quarter 2019

VCEL : 14.38 (+1.05%)
Vericel to Report First-Quarter 2020 Financial Results on May 5, 2020

Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced the following webcast and conference call to discuss its first-quarter...

VCEL : 14.38 (+1.05%)
Vericel Announces Change to a Virtual Meeting Format For 2020 Annual Meeting of Shareholders

Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that as a result of the COVID-19 pandemic, to support the health...

VCEL : 14.38 (+1.05%)
Vericel to Present at the 19th Annual Needham Healthcare Conference on Tuesday, April 14, 2020

Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, president and CEO, will present the latest company...

VCEL : 14.38 (+1.05%)
Vericel Provides Business and Financial Updates

First Quarter Preliminary Unaudited Product Revenues Increased Approximately 21% Over First Quarter 2019

VCEL : 14.38 (+1.05%)
Zacks.com featured highlights include: Envestnet, First Majestic Silver, Myriad Genetics, Vericel and Casella Waste Systems

Zacks.com featured highlights include: Envestnet, First Majestic Silver, Myriad Genetics, Vericel and Casella Waste Systems

MYGN : 14.53 (+0.83%)
CWST : 50.95 (-1.20%)
ENV : 72.61 (+0.86%)
AG : 10.01 (+7.52%)
VCEL : 14.38 (+1.05%)
Dump These 5 Toxic Stocks Right Away

Accurately identifying toxic stocks and abandoning or short selling those at the right time is the key to safeguard your portfolio from big losses.

MYGN : 14.53 (+0.83%)
CWST : 50.95 (-1.20%)
ENV : 72.61 (+0.86%)
AG : 10.01 (+7.52%)
VCEL : 14.38 (+1.05%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Trade VCEL with:

Business Summary

Vericel Corporation is focused on developing patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions. The company markets two autologous cell therapy products in the United States: Carticel (R) for the treatment of cartilage defects in the...

See More

Key Turning Points

2nd Resistance Point 14.95
1st Resistance Point 14.59
Last Price 14.38
1st Support Level 13.90
2nd Support Level 13.57

See More

52-Week High 19.95
Fibonacci 61.8% 14.92
Last Price 14.38
Fibonacci 50% 13.37
Fibonacci 38.2% 11.81
52-Week Low 6.78

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar